Altimmune, Inc.ALTEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies, vaccines, and peptide-based therapies. Its pipeline covers infectious disease prevention, liver disease treatments, and metabolic disorder therapies, serving global biopharmaceutical and healthcare markets while advancing candidates through clinical trials.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 7.50% | 4.0M | — | 2024-01-26 |
| The Vanguard Group | 6.65% | 3.6M | — | 2024-02-13 |
| Ameriprise Financial, | 5.45% | 3.9M | ▼ -2.34pp | 2024-11-14 |
| NOS. of Above Persons | 5.10% | 2.8M | ▲ +5.10pp | 2024-02-14 |
| STATE STREET CORPORATION | 4.80% | 3.4M | ▼ -0.71pp | 2024-10-17 |
| Millennium Management LLC | 0.20% | 144.2K | ▼ -5.20pp | 2024-10-16 |
| Nuveen Asset Management, LLC | 0.01% | 6.7K | flat | 2024-02-14 |
| S.S. OR | 0.00% | — | — | 2024-02-12 |
Insider Transactions
Net 90d: +$198.4K · buys $198.4K / sells $0Range:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-06 | GILL JOHN | Director | Buy (open market) | 9.2K | $3.41 | $31.3K |
| 2026-04-01 | WEAVER GREGORY L | Chief Financial Officer | Buy (open market) | 10.0K | $3.15 | $31.5K |
| 2026-04-01 | Durso Jerome Benedict | President and CEO | Buy (open market) | 15.0K | $3.14 | $47.1K |
| 2026-03-06 | WEAVER GREGORY L | Chief Financial Officer | Buy (open market) | 5.0K | $3.54 | $17.7K |
| 2026-03-06 | Durso Jerome Benedict | President and CEO | Buy (open market) | 20.0K | $3.54 | $70.8K |
| 2026-02-02 | Roberts M Scot | Chief Scientific Officer | Option exercise | 7.8K | $0.00 | $0 |
| 2026-01-31 | Roberts M Scot | Chief Scientific Officer | Grant | 5.6K | $3.07 | $17.1K |
| 2026-01-31 | Garg Vipin K | Director | Grant | 6.9K | $3.07 | $21.3K |
| 2026-01-31 | Jordt Raymond M | Chief Business Officer | Grant | 4.6K | $3.07 | $14.0K |
| 2026-01-30 | Roberts M Scot | Chief Scientific Officer | Option exercise | 9.3K | $0.00 | $0 |
1–10 of 11
Page 1 / 2